Screener
Haemonetics HAE Apheresis — Operating Income (Loss)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 |
|---|---|---|
| Cost of goods sold | $84,131 | $75,865 |
| Selling, general and administrative | 44,264 | 39,880 |
| Research and development | 6,378 | 6,816 |
| Apheresis operating income | $56,545 | $59,175 |
| MedSurg | ||
| Cost of goods sold | $50,368 | $50,216 |
| Selling, general and administrative | 65,160 | 62,323 |
| Research and development | 9,820 | 8,742 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Haemonetics's apheresis — operating income (loss)?
- Haemonetics (HAE) reported apheresis — operating income (loss) of $56.55M in Q2 2026.
- What does apheresis — operating income (loss) mean?
- This is the profit or loss generated by the Apheresis segment after deducting all operating expenses, including cost of goods sold, SG&A, and R&D, from total net revenues. It provides a clear view of the segment's core operational profitability and its contribution to the company's consolidated earnings. It is the primary metric for evaluating the segment's financial health and management's operational execution.
Ask your AI about Haemonetics's apheresis — operating income (loss).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude